by Barry101 | Apr 7, 2025 | Press Release
OCALA, Fla., April 07, 2025 — AIM ImmunoTech Inc. (“AIM” or the “Company”) (OTC Pink: AIMI) – an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and...
by Barry101 | Apr 4, 2025 | Press Release
OCALA, Fla., April 04, 2025 — AIM ImmunoTech Inc. (“AIM” or the “Company”) (NYSE American: AIM), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and...
by Barry101 | Mar 27, 2025 | Press Release
Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer space Expected milestones over the course of the next 18 months provide significant value-driving...
by Barry101 | Mar 11, 2025 | Press Release
On-demand video webcast now available Includes latest updates on pancreatic cancer and bird flu clinical trials OCALA, Fla., March 11, 2025 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced its...
by Barry101 | Feb 28, 2025 | Press Release
Proposed study of Ampligen as a vaccine adjuvant to increase cross-reactivity to influenza strainsOCALA, Fla., Feb. 28, 2025 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that Paul Goepfert, MD, of...
by Barry101 | Feb 26, 2025 | Press Release
OCALA, Fla., Feb. 26, 2025 — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it received notice from the NYSE American (the “American”) that the American has accepted the Company’s...
